Jasper Therapeutics Inc
Change company Symbol lookup
Select an option...
JSPR Jasper Therapeutics Inc
RILY B Riley Financial Inc
NVDA NVIDIA Corp
BIIO Bionovate Technologies Corp
PGWFF PGG Wrightson Ltd
CRNX Crinetics Pharmaceuticals Inc
NDAQ Nasdaq Inc
PML PIMCO Municipal Income Fund II
BBLN Babylon Holdings Ltd
NEPT Neptune Wellness Solutions Inc
Go

Company profile

Jasper Therapeutics, Inc., formerly Amplitude Healthcare Acquisition Corporation, is a biotechnology company focused on hematopoietic cell transplant therapies. The Company has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The Company also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.

Closing Price
$8.48
Day's Change
0.48 (6.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.55
Day's Low
7.87
Volume
(Heavy Day)
Volume:
379,772

10-day average volume:
303,629
379,772

Jasper Therapeutics started at outperform with $21 stock price target at Oppenheimer

8:44 am ET October 13, 2021 (MarketWatch)
Print
	

(END) Dow Jones Newswires

October 13, 2021 08:44 ET (12:44 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.